====== Kyla Hildebrand ======

{{ ::kyla-hildebrand-2112-20211201.jpeg?150|}}

Dr. **Kyla Hildebrand** is a Canadian allergist and clinical immunologist based in [[canada:british_columbia:Vancouver]], [[canada:British Columbia]]. She is notable in the [[COVID-19 pandemic]] for her role in approving [[COVID-19 vaccines]] on the [[National Advisory Committee on Immunization]] (NACI).

===== Education =====

Hildebrand completed medical school at the [[University of Manitoba]] in 2005, Pediatrics Residency at the [[University of Alberta]], and a fellowship in Clinical Immunology and Allergy at the [[University of Toronto]].((//Hildebrand, Kyla Jade - Doctor Details.// (2013, June 3). College of Physicians and Surgeons of Ontario. https://archive.ph/b2elA)) ((//Kyla Hildebrand - Clinical Assistant Professor of Pediatrics Allergy and Immunology in Vancouver, British Columbia, Canada.// eMedEvents. Retrieved April 18, 2022, from https://web.archive.org/web/20220418074053/https://www.emedevents.com/speaker-profile/kyla-hildebrand)) She completed a Master of Science in Community Health at the University of Toronto and was the 2010 recipient of the [[Royal College of Physicians and Surgeons of Canada]] Fellowship for Studies in Medical Education.

===== Affiliations =====

Hildebrand began her academic career at the [[University of Western Ontario]].

Hildebrand is a researcher at the [[BC Children's Hospital Research Institute]].((//Kyla Hildebrand.// BC Children’s Hospital Research Institute. Retrieved April 17, 2022, from https://www.bcchr.ca/khildebrand)) She is also a clinical associate professor in the Division of Allergy and Immunology, Department of Pediatrics, Faculty of Medicine, at the [[University of British Columbia]].((//Welcome to Dr. Kyla Hildebrand | Department of Pediatrics.// (2013, September 3). University of British Columbia. https://archive.ph/BMCDk))

Hildebrand sits on the board of directors for the [[Canadian Society of Allergy and Clinical Immunology]] (CSACI), and has received honoraria from the [[BC Society of Allergy and Immunology]] (BCSAI).((Li, L. D. X., Abrams, E. M., Lavine, E., Hildebrand, K., & Mack, D. P. (2021). //CSACI position statement: transition recommendations on existing epinephrine autoinjectors.// Allergy, Asthma & Clinical Immunology, 17(1). https://doi.org/10.1186/s13223-021-00634-2)) ((//Program Directors.// Canadian Society of Allergy and Clinical Immunology. Retrieved April 18, 2022, from https://archive.ph/EAVaX))

===== Research =====

==== Funding ====

Hildebrand has received funding from [[pharmaceutical_companies:AstraZeneca]], [[pharmaceutical_companies:Boehringer Ingelheim]], [[pharmaceutical_companies:CSL Behring]], [[pharmaceutical_companies:MEDA Pharmaceuticals]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Pfizer]], [[pharmaceutical_companies:Shire Pharma]], [[pharmaceutical_companies:Stallergenes Greer]], [[pharmaceutical_companies:Takeda]], [[pharmaceutical_companies:Teva]], [[pharmaceutical_companies:Aralez]] and
[[pharmaceutical_companies:Pediapharm]] as recently as 2018.((Quirt, J., Hildebrand, K. J., Mazza, J., Noya, F., & Kim, H. (2018). //Asthma.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0279-0)) ((Chan, E. S., Abrams, E. M., Hildebrand, K. J., & Watson, W. (2018). //Early introduction of foods to prevent food allergy.// Allergy, Asthma & Clinical Immunology, 14(S2). https://doi.org/10.1186/s13223-018-0286-1)) She has also received speakers fees from [[pharmaceutical_companies:Novartis]], and paid travel expenses for [[AllerGen]].((Soller, L., Abrams, E. M., Carr, S., Kapur, S., Rex, G. A., Leo, S., Lidman, P. G., Yeung, J., Vander Leek, T. K., McHenry, M., Wong, T., Cook, V. E., Hildebrand, K. J., Gerstner, T. V., Mak, R., Lee, N. J., Cameron, S. B., & Chan, E. S. (2019). //First real-world safety analysis of preschool peanut oral immunotherapy.// The Journal of Allergy and Clinical Immunology: In Practice, 7(8), 2759-2767.e5. https://doi.org/10.1016/j.jaip.2019.04.010))

She has also served as a consultant for [[Food Allergy Canada]], and has received honoraria from [[Health Canada]]. She received a research grant from the [[Canadian Allergy, Asthma, and Immunology Foundation]].((Waserman, S., Cruickshank, H., Hildebrand, K. J., Mack, D., Bantock, L., Bingemann, T., Chu, D. K., Cuello-Garcia, C., Ebisawa, M., Fahmy, D., Fleischer, D. M., Galloway, L., Gartrell, G., Greenhawt, M., Hamilton, N., Hourihane, J., Langlois, M., Loh, R., Muraro, A., & Rosenfield, L. (2021). //Prevention and management of allergic reactions to food in child care centers and schools: Practice guidelines.// Journal of Allergy and Clinical Immunology, 147(5), 1561–1578. https://doi.org/10.1016/j.jaci.2021.01.034))

[[Food Allergy Canada]] is partnered with [[pharmaceutical_companies:Pfizer]].((//Who we work with.// Food Allergy Canada. Retrieved April 18, 2022, from https://archive.ph/e2uhY))

She has received further funding from [[Genome British Columbia]] and the [[BC Children's Hospital Foundation]].((Blanchard-Rohner, G., Ragotte, R. J., Junker, A. K., Sharma, M., Del Bel, K. L., Lu, H. Y., Erdle, S., Chomyn, A., Gill, H., Tucker, L. B., Schreiber, R. A., Rozmus, J., Biggs, C. M., Hildebrand, K. J., Wu, J., Stockler-Ipsiroglu, S., & Turvey, S. E. (2021). //Idiopathic splenomegaly in childhood and the spectrum of RAS-associated lymphoproliferative disease: a case report.// BMC Pediatrics, 21(1). https://doi.org/10.1186/s12887-021-02508-3)) ((Roberts, H., Soller, L., Ng, K., Chan, E. S., Roberts, A., Kang, K., Hildebrand, K. J., & Wong, T. (2020). //First pediatric electronic algorithm to stratify risk of penicillin allergy.// Allergy, Asthma & Clinical Immunology, 16(1). https://doi.org/10.1186/s13223-020-00501-6)) She has published NACI papers with funding from the [[Public Health Agency of Canada]].((Dayneka, N., Jensen, C., & Hildebrand, K. (2020). //Canadian Immunization Guide: “Anaphylaxis and other acute reactions following vaccination” chapter update.// Canada Communicable Disease Report, 46(1112), 384–386. https://doi.org/10.14745/ccdr.v46i1112a04))